Literature DB >> 15128465

Calcium antagonist strategies for coronary artery disease.

John M Flack1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15128465     DOI: 10.1007/s11906-004-0063-z

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  4 in total

1.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

2.  Ramipril and the development of diabetes.

Authors:  S Yusuf; H Gerstein; B Hoogwerf; J Pogue; J Bosch; B H Wolffenbuttel; B Zinman
Journal:  JAMA       Date:  2001-10-17       Impact factor: 56.272

3.  Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.

Authors:  Richard B Devereux; Björn Dahlöf; Sverre E Kjeldsen; Stevo Julius; Peter Aurup; Gareth Beevers; Jonathan M Edelman; Ulf de Faire; Frej Fyhrquist; Sigrid Helle Berg; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Steven Snapinn; Hans Wedel
Journal:  Ann Intern Med       Date:  2003-08-05       Impact factor: 25.391

4.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.